Meeder Asset Management
MNPR icon

Meeder Asset Management’s Monopar Therapeutics MNPR Stock Holding History

Meeder Asset Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$132K Buy
1,651
+262
+19% +$28.1K 0.01% 342
2026
Q2 		$129K Buy
1,389
+752
+118% +$46.6K 0.01% 342
2026
Q1 		$34.9K Sell
637
-357
-36% -$21.6K ﹤0.01% 493
2025
Q4 		$64.9K Buy
+994
New +$81.2K ﹤0.01% 372

Other funds holding MNPR

SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Meeder Asset Management's MNPR Position: Q3 2026 in Review

Meeder Asset Management increased its Monopar Therapeutics (MNPR) stake by 19% in Q3 2026, buying an estimated $28.1K and bringing the position to 1,651 shares worth $132K. The position accounts for 0.01% of the portfolio, ranked #342.

Meeder Asset Management first reported a position in MNPR in Q4 2025 and has held it in 4 quarters since. 47 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.

  • Meeder Asset Management held 1,651 shares of Monopar Therapeutics worth $132K as of Q3 2026.
  • Meeder Asset Management bought 262 Monopar Therapeutics shares in Q3 2026, an estimated $28.1K.
  • Monopar Therapeutics made up 0.01% of Meeder Asset Management's portfolio in Q3 2026, its #342 holding.
  • Meeder Asset Management first reported a position in Monopar Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 47 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.

Based on Meeder Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.